Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Kazumasa Komura; Teruo Inamoto; Tomoaki Takai; Taizo Uchimoto; Kenkichi Saito; Naoki Tanda; Junko Kono; Koichiro Minami; Hirohumi Uehara; Yutaka Fujisue; Kiyoshi Takahara; Hajime Hirano; Hayahito Nomi; Toshikazu Watsuji; Satoshi Kiyama; Haruhito Azuma

doi:10.1007/s00345-013-1215-z

Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Kazumasa Komura, Teruo Inamoto, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Junko Kono, Koichiro Minami, Hirohumi Uehara, Yutaka Fujisue, Kiyoshi Takahara, Hajime Hirano, Hayahito Nomi, Toshikazu Watsuji, Satoshi Kiyama, Haruhito Azuma

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate^® for patients with localized prostate cancer.

Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.

Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.

Conclusions: Single-session HIFU treatment using the Sonablate^® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

Original language	English
Pages (from-to)	1339-1345
Number of pages	7
Journal	World Journal of Urology
Volume	32
Issue number	5
DOIs	https://doi.org/10.1007/s00345-013-1215-z
Publication status	Published - 10-2013
Externally published	Yes

All Science Journal Classification (ASJC) codes

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00345-013-1215-z

Cite this

Komura, K., Inamoto, T., Takai, T., Uchimoto, T., Saito, K., Tanda, N., Kono, J., Minami, K., Uehara, H., Fujisue, Y., Takahara, K., Hirano, H., Nomi, H., Watsuji, T., Kiyama, S., & Azuma, H. (2013). Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy. World Journal of Urology, 32(5), 1339-1345. https://doi.org/10.1007/s00345-013-1215-z

@article{02f4b3e3a8c848e3a6dc3af36610b6bb,

title = "Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy",

abstract = "Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate{\textregistered} for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D{\textquoteright}Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D{\textquoteright}amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate{\textregistered} seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.",

author = "Kazumasa Komura and Teruo Inamoto and Tomoaki Takai and Taizo Uchimoto and Kenkichi Saito and Naoki Tanda and Junko Kono and Koichiro Minami and Hirohumi Uehara and Yutaka Fujisue and Kiyoshi Takahara and Hajime Hirano and Hayahito Nomi and Toshikazu Watsuji and Satoshi Kiyama and Haruhito Azuma",

note = "Publisher Copyright: {\textcopyright} 2013, The Author(s).",

year = "2013",

month = oct,

doi = "10.1007/s00345-013-1215-z",

language = "English",

volume = "32",

pages = "1339--1345",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

Komura, K, Inamoto, T, Takai, T, Uchimoto, T, Saito, K, Tanda, N, Kono, J, Minami, K, Uehara, H, Fujisue, Y, Takahara, K, Hirano, H, Nomi, H, Watsuji, T, Kiyama, S & Azuma, H 2013, 'Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy', World Journal of Urology, vol. 32, no. 5, pp. 1339-1345. https://doi.org/10.1007/s00345-013-1215-z

TY - JOUR

T1 - Single session of high-intensity focused ultrasound for localized prostate cancer

T2 - treatment outcomes and potential effect as a primary therapy

AU - Komura, Kazumasa

AU - Inamoto, Teruo

AU - Takai, Tomoaki

AU - Uchimoto, Taizo

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Kono, Junko

AU - Minami, Koichiro

AU - Uehara, Hirohumi

AU - Fujisue, Yutaka

AU - Takahara, Kiyoshi

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Watsuji, Toshikazu

AU - Kiyama, Satoshi

AU - Azuma, Haruhito

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

AB - Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

UR - http://www.scopus.com/inward/record.url?scp=84887960475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887960475&partnerID=8YFLogxK

U2 - 10.1007/s00345-013-1215-z

DO - 10.1007/s00345-013-1215-z

M3 - Article

C2 - 24270943

AN - SCOPUS:84887960475

SN - 0724-4983

VL - 32

SP - 1339

EP - 1345

JO - World Journal of Urology

JF - World Journal of Urology

IS - 5

ER -

Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this